<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="Research Article" dtd-version="1.0"><front><journal-meta><journal-id journal-id-type="pmc">srjms</journal-id><journal-id journal-id-type="pubmed">SRJMS</journal-id><journal-id journal-id-type="publisher">SRJMS</journal-id><issn>2788-9483</issn></journal-meta><article-meta><article-id pub-id-type="doi">https://doi.org/10.47310/srjms.2026.v06i01.004</article-id><title-group><article-title>Evaluation of Decorin (DCN) Gene Expression as a Potential Biomarker in Patients with Severe Knee Osteoarthritis: A Pilot Study</article-title></title-group><abstract>Background: Knee Osteoarthritis (KOA) is a degenerative pathology marked by progressive cartilage attrition and extracellular matrix (ECM) disruption, where Decorin (DCN) is a small, leucine-rich proteoglycan that provides a binding mechanism in chondrocyte biology, making it an important structural component for matrix integrity and the biomechanical function of cartilage. Objective: To quantify DCN&amp;nbsp;gene expression in KOA patients and evaluate its correlation with clinical severity. Methods: mRNA was extracted from whole blood samples of KOA patients (n=10) and healthy controls (n=10). Relative expression was determined via RT-qPCR using the 2-ΔΔCt method, normalized to GAPDH. Statistical analysis and visualization were performed using GraphPad Prism v.6. Results: A highly significant upregulation of DCN expression was observed in the KOA cohort compared to controls (p&amp;lt;0.001), showing a fold-change of approximately 12. High expression levels demonstrated a strong positive correlation with advanced disease stages. Conclusion: The marked elevation of DCN suggests a compensatory mechanism to mitigate ECM degradation. These findings highlight DCN as a sensitive molecular biomarker for KOA progression and therapeutic monitoring.</abstract></article-meta></front><body /><back /></article>